Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Morepen Laboratories Limited

Market Cap 18.52B 196M 172M 158M 148M 278M 282M 1.9B 736M 9.09B 734M 718M 31.58B P/E 2024
22.4x
P/E 2025 21.8x
Enterprise Value 18.52B 196M 172M 158M 148M 278M 282M 1.9B 736M 9.09B 734M 718M 31.58B EV / Sales 2024
1.27x
EV / Sales 2025 1.45x
Free-Float
57.31%
Yield 2024 *
-
Yield 2025 0.42%
1 day+0.08%
1 week+1.67%
Current month+21.05%
1 month+19.72%
3 months+43.20%
6 months+25.82%
Current year+27.44%
1 week 48.6
Extreme 48.6
53.24
1 month 41.38
Extreme 41.38
53.66
Current year 33.05
Extreme 33.05
53.66
1 year 33.05
Extreme 33.05
66.4
3 years 28.6
Extreme 28.6
100.9
5 years 23.6
Extreme 23.6
100.9
10 years 7.2
Extreme 7.2
100.9
Manager TitleAgeSince
Chief Executive Officer 62 01/02/1992
Director of Finance/CFO 59 03/04/2002
Compliance Officer 40 12/11/2018
Director TitleAgeSince
Chairman 62 01/02/1992
Director/Board Member 57 13/08/2019
Director/Board Member 57 13/08/2019
Change 5-day change 1-year change 3-year change Capi.($)
+0.10%+1.67% - - 303M
+0.45%-1.37%+43.66%+141.28% 987B
+3.37%+1.66%+58.00%+44.48% 576B
+2.07%+5.52%+27.75%+72.72% 415B
+0.25%-1.30%+22.76%+15.66% 320B
+2.26%+2.30%+30.42%+18.98% 278B
+2.61%+3.11%+29.81%+36.09% 279B
+2.60%+9.79%-31.71%-43.45% 208B
+0.66%-0.24%+27.37%+52.79% 187B
+0.14%-1.71%+17.76%+61.42% 155B
Average +1.43%+1.51%+25.09%+44.44% 378.36B
Weighted average by Cap. +1.56%+0.73%+33.29%+66.37%

Financials

2024 2025
Net sales 17.02B 180M 158M 145M 136M 255M 259M 1.75B 676M 8.35B 674M 660M 29.02B 18.12B 191M 168M 155M 145M 272M 276M 1.86B 720M 8.89B 718M 702M 30.89B
Net income 962M 10.15M 8.92M 8.22M 7.69M 14.41M 14.66M 98.67M 38.19M 472M 38.11M 37.29M 1.64B 1.18B 12.46M 10.94M 10.09M 9.44M 17.69M 17.99M 121M 46.88M 579M 46.77M 45.76M 2.01B
Net Debt 121M 1.27M 1.12M 1.03M 964K 1.81M 1.84M 12.37M 4.79M 59.14M 4.78M 4.67M 206M -928K -9.8K -8.61K -7.93K -7.42K -13.91K -14.14K -95.22K -36.86K -455K -36.78K -35.98K -1.58M
Logo Morepen Laboratories Limited
Morepen Laboratories Limited is a pharmaceutical company. The Company is in the business of manufacturing, producing, developing and marketing a range of active pharmaceutical ingredients (APIs), branded and generic formulations and also home health products. Its APIs include Apixaban, Edoxaban, Linagliptin, Linagliptin + Metformin, Empagliflozin, Empagliflozin + Metformin, Atorvastatin, Rosuvastain, Rivaroxaban, Fexofenadine, Montelukast (Oral), Montelukast (Chewable), Montelukast Sodium, among others. Its finished formulations include Intebact Capsules, Intelicaps Lax, Rythmix Kid Drop, Rythmix Kid Syrup, Kompact Powder, Saltum and Acifix 3X Suspension among others. Its home health products include Dr. Morepen Nebulizer Model CN-11, Dr. Morepen Pulse Oximeter Model PO-12A, Dr. Morepen Breathe Free Vaporizer Model VP-06 and Dr. Morepen Pulse Oximeter Model PO-12A, among others. Its subsidiaries include Dr. Morepen Limited, Morepen Devices Limited, and Total Care Limited.
Employees
1,814
Date Price Change Volume
24/06/26 INR 52.35 +0.10% 4,536,071
23/06/26 INR 52.30 +4.33% 18,278,357
22/06/26 INR 50.13 +1.27% 4,697,621
19/06/26 INR 49.50 -3.00% 6,160,692
18/06/26 INR 51.03 -0.87% 5,910,588
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!